Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CDK2 | P24941 | 3/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23337430 | 0.78 | ALDH1A1 (0.43) | GRM5ALDH1A1HTR1ADRD2HTR2A | |
| SCHEMBL29918309 | 0.71 | CCNA2 (0.39) | ALDH1A1HTR1ADRD2HTR2ACCNA2 | |
| SCHEMBL22216418 | 0.71 | ALDH1A1 (0.46) | GRM5ALDH1A1HTR1ADRD2HTR2A | |
| SCHEMBL29918363 | 0.69 | HTR1A (0.53) | ALDH1A1HTR1ADRD2HTR2ACCNA2 | |
| SCHEMBL22216186 | 0.68 | GRM5 (0.47) | GRM5CCNA2CDK2NOTUMACVRL1 | |
| SCHEMBL22048360 | 0.68 | PLK1 (0.50) | GRM5HTR1ADRD2HTR2A | |
| SCHEMBL25913022 | 0.68 | GRM5 (0.40) | GRM5NOTUMACVRL1ACVR1 | |
| SCHEMBL23336559 | 0.68 | HTR1A (0.35) | GRM5HTR1ADRD2HTR2ANOTUM | |
| SCHEMBL22057225 | 0.67 | JAK2 (0.43) | ALDH1A1NOTUM | |
| SCHEMBL22048359 | 0.66 | GRM5 (0.50) | GRM5HTR1ADRD2HTR2AACVRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411429-A1 | CONDENSED PYRIDAZINE OR PYRIMIDINE AS BTK INHIBITORS | BIOGEN MA INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2021133894-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2021-07-01 | — | — | WO | disclosed |
| WO-2021087086-A1 | CONDENSED PYRIDAZINE OR PYRIMIDINE AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411429-A1 | CONDENSED PYRIDAZINE OR PYRIMIDINE AS BTK INHIBITORS | BTK, CDK2, SYK | GRM5 3081/4885ALDH1A1 2770/4885HTR1A 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.